Meniere Disease - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Meniere Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Meniere Disease - Pipeline Review, H2 2016', provides an overview of the Meniere Disease pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Meniere Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Meniere Disease and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meniere Disease
- The report reviews pipeline therapeutics for Meniere Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Meniere Disease therapeutics and enlists all their major and minor projects
- The report assesses Meniere Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Meniere Disease

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Meniere Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Meniere Disease Overview 6
Therapeutics Development 7
Pipeline Products for Meniere Disease - Overview 7
Meniere Disease - Therapeutics under Development by Companies 8
Meniere Disease - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Meniere Disease - Products under Development by Companies 13
Meniere Disease - Companies Involved in Therapeutics Development 14
Orbis Biosciences Inc 14
Otonomy, Inc. 15
Quark Pharmaceuticals, Inc. 16
Sound Pharmaceuticals, Inc. 17
Synphora AB 18
Meniere Disease - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
betamethasone valerate ER - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
dexamethasone acetate SR - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
latanoprost - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
OR-105 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
QPHL-2 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
SPI-1005 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Meniere Disease - Dormant Projects 38
Meniere Disease - Product Development Milestones 39
Featured News & Press Releases 39
Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients 39
Mar 23, 2016: Otonomy Initiates Patient Enrollment in Second Phase 3 Clinical Trial of OTO-104 in Meniere's Disease 39
Jan 26, 2016: Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss 40
Nov 18, 2015: Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere Disease 40
Sep 24, 2015: Otonomy to Present Results for OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting 41
Sep 09, 2015: Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere Disease 41
May 21, 2015: Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere Disease 41
Apr 20, 2015: Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere Disease Patients 42
Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere Disease 43
Oct 09, 2014: Otonomy Enrolls First Meniere Disease Patients in OTO-104 Multiple-Dose Safety Study 43
Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere Disease 43
Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere Disease At International Conference 44
Apr 28, 2011: Otonomy Announces Positive Results From Phase Ib Study Of OTO-104 In Meniere's Disease 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Number of Products under Development for Meniere Disease, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Comparative Analysis by Unknown Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Meniere Disease - Pipeline by Orbis Biosciences Inc, H2 2016 14
Meniere Disease - Pipeline by Otonomy, Inc., H2 2016 15
Meniere Disease - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 16
Meniere Disease - Pipeline by Sound Pharmaceuticals, Inc., H2 2016 17
Meniere Disease - Pipeline by Synphora AB, H2 2016 18
Assessment by Monotherapy Products, H2 2016 19
Number of Products by Stage and Target, H2 2016 21
Number of Products by Stage and Mechanism of Action, H2 2016 23
Number of Products by Stage and Route of Administration, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 27
Meniere Disease - Dormant Projects, H2 2016 38